Dr. Jamie N. Topper is a managing general partner of Frazier Healthcare Partner’s life sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in that same year. Throughout his 12 years as a general partner, Dr. Topper has invested across over 20 companies encompassing a broad spectrum of life science and biopharmaceutical companies.
He has led and served as a board member for many of Frazier’s successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Calistoga Pharmaceuticals (co-founder, sold to Gilead Sciences), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola (co-founder, NASDAQ: PTLA), CoTherix (sold to Actelion) and Threshold (NASDAQ: THLD). He currently represents Frazier on the boards of Alcresta, Allena Pharmaceuticals, Alpine Immune Sciences, AnaptysBio (NASDAQ: ANAB), Aptinyx, Entasis Therapeutics and Millendo Therapeutics. He is also a board observer for Gritstone Oncology.
Prior to joining Frazier, Dr. Topper was the head of cardiovascular R&D at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Before the merger of COR and Millennium, he served as the vice president of biology at COR and was responsible for all research activities. He served on the medical school faculties at Stanford and Harvard Medical School prior to joining COR.
Dr. Topper received his M.D. and Ph.D. in biophysics from Stanford and holds a B.S. from the University of Michigan. He completed his postgraduate training in internal medicine and cardiovascular disease at the Brigham and Women’s Hospital in Boston. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford.
In 2011 and 2016, Dr. Topper was named to the Midas List of leading venture capitalists. In 2013, he was recognized by Forbes as one of the top 10 healthcare investors.